Administering erythropoietin to rats with diabetic neuropathy prevents and partly reverses biochemical and physical deficits in nerve and muscle. Certain drawbacks limit the immediate applicability of this approach in patients.
No takes yet. Share an insight, caveat, or question.
Stuart A. Lipton (2004) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: